Miguel
Fernández de Sanmamed Gutiérrez
Consultor Médico
Yonsei University
Seúl, Corea del SurPublicaciones en colaboración con investigadores/as de Yonsei University (1)
2019
-
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 6, pp. 1046-1060